Advaxis Seals Collaboration Agreement With City of Hope

Published: 19-Aug-2009

For the development of a vaccine to treat certain forms of leukemia and lymphoma

Advaxis has formed a collaboration with investigators at City of Hope. It is for the development of a vaccine to treat certain forms of leukemia and lymphoma, based upon the company’s proprietary Lm vaccine technology platform.

The investigators at City of Hope are studying a vaccine provided by Advaxis directed against the tumor associated antigen, WT-1.

The company said that in a recent Advaxis phase 1 clinical trial, it was found that a similar live Lm vaccine directed against the tumor-associated antigen, HPV-16-E7, was safely administered to women with advanced metastatic cancer of the cervix.

However, the first trial of the Lm vaccine in humans was limited and not designed or powered to test therapeutic efficacy, Advaxis believes an efficacy signal was observed that supports additional investigation into the use of this unique vaccine technology for the treatment of cancer.

Thomas Moore, CEO at Advaxis, said: Advaxis now has nine distinct cancer fighting constructs under various stages of development, four through academic collaborations. As scientific excitement around Listeria technology grows, we believe many more opportunities will develop. These collaborations add to our overall understanding of Listerial vaccines, generate further scientific standing and accelerate the development of our pipeline. This new opportunity expands our potential pipeline beyond solid tumors.

Tell your friend about this article